Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation

Among the several next-generation tyrosine kinase inhibitors (TKIs) tested against uncommon EFGR alterations, poziotinib has been demonstrated to be a powerful agent for metastatic non-small-cell lung cancer (mNSCLC) with aberrations in HER2 exon 20, and FDA approval is being sought in the previousl...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Arsela Prelaj, Achille Bottiglieri, Gajanan Bhat, Rocky Washington, Giuseppina Calareso, Gabriella Francesca Greco, Roberto Ferrara, Marta Brambilla, Alessandro De Toma, Mario Occhipinti, Sara Manglaviti, Alberto Soro, Monica Ganzinelli, Giuseppe Lo Russo, Claudia Proto
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2022-06-01
Ráidu:	Frontiers in Oncology
Fáttát:	poziotinib NSCLC lung cancer exon 20 insertion mutation EGFR exon 20 insertion (ex20ins)
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fonc.2022.902967/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!